GSWM
NVAX icon

Golden State Wealth Management’s Novavax NVAX Stock Holding History

Golden State Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$16 – 1674
2026
Q1 		$16 Hold
2
– – ﹤0.01% 1594
2025
Q4 		$13 Hold
2
– – ﹤0.01% 1668
2025
Q3 		$17 Buy
+2
New +$16 ﹤0.01% 1654

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Golden State Wealth Management's NVAX Position: Q2 2026 in Review

Golden State Wealth Management sold out of Novavax (NVAX) in Q2 2026, closing a stake of 2 shares — an estimated $16 sold.

Golden State Wealth Management first reported a position in NVAX in Q3 2025 and held it in 3 quarters. The position peaked at $17 in Q3 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Golden State Wealth Management reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
  • Golden State Wealth Management sold 2 Novavax shares in Q2 2026, an estimated $16.
  • Golden State Wealth Management first reported a position in Novavax in Q3 2025 and held it in 3 quarters.
  • Golden State Wealth Management's Novavax position peaked at $17 in Q3 2025.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.